Drug
Mid Dose Bid BI 3731579
Mid Dose Bid BI 3731579: highest development phase Phase 1, developed by Boehringer Ingelheim. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| Mid-dose bid BI 3731579 NCT06716190 | Phase 1 | Healthy |
Latest
No recent events.
Follow Mid Dose Bid BI 3731579 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.